Literature DB >> 8691844

Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma.

D F Alonso1, E F Farías, A Urtreger, V Ladeda, M C Vidal, E Bal De Kier Joffé.   

Abstract

We characterized a new mammary tumor cell line, F3II, previously established in vitro from a clonal subpopulation of the BALB/c transplantable mammary adenocarcinoma M3, moderately metastatic to lung. The F3II cell line has been passaged > 50 times. It has grown as elongated cells adherent to the bottom of the flask. Cytogenetic studies showed that F3II cultures were nearly triploid. Tumor cells expressed fibronectin and showed high levels of cell-surface urokinase, a key protease in invasion and metastasis. F3II cells grew as poorly differentiated, spindle-cell carcinoma tumors (sarcomatoid carcinomas) with a prominent local invasiveness, a high angiogenic response, and a 90-100% incidence of lung metastases when inoculated s.c. into syngeneic mice. Ultrastructural and immunocytochemical analysis revealed characteristic features of carcinomas. Our data suggest that F3II is less differentiated and more aggressive than the original tumor line, supporting the notion that mammary carcinomas are heterogeneous neoplasms and contain subpopulations with diverse biologic behavior. The F3II mouse mammary sarcomatoid carcinoma line is a suitable model to examine antiinvasive, antiangiogenic, and antimetastatic agents.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8691844     DOI: 10.1002/(SICI)1096-9098(199608)62:4<288::AID-JSO14>3.0.CO;2-1

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  16 in total

1.  Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells.

Authors:  Hernán G Farina; Débora R Bublik; Daniel F Alonso; Daniel E Gomez
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

2.  Experimental studies of a vaccine formulation of recombinant human VEGF antigen with aluminum phosphate.

Authors:  Lincidio Pérez Sánchez; Yanelys Morera Díaz; Mónica Bequet-Romero; Gerardo Ramses Hernández; Yadira Rodríguez; Jorge Castro Velazco; Pedro Puente Pérez; Marta Ayala Avila; Jorge V Gavilondo
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Efficacy of direct current generated by multiple-electrode arrays on F3II mammary carcinoma: experiment and mathematical modeling.

Authors:  Narciso Antonio Villar Goris; Jorge Luis García Rodríguez; Maraelys Morales González; Beatriz Olivares Borges; Dasha Fuentes Morales; Enaide Maine Calzado; Antonio Rafael Selva Castañeda; Leonardo Mesa Torres; Juan Ignacio Montijano; Victoriano Gustavo Sierra González; Daniel Jay Pérez; Oscar Ortiz Posada; Janet Avellanet Martínez; Arlem García Delgado; Karina García Martínez; Mayrel Labrada Mon; Kalet León Monzón; Héctor Manuel Camué Ciria; Luis Enrique Bergues Cabrales
Journal:  J Transl Med       Date:  2020-05-07       Impact factor: 5.531

4.  Murine Mammary Carcinoma Induces Chronic Systemic Inflammation and Immunosuppression in BALB/c Mice.

Authors:  Dasha Fuentes; Alejandro Cabezas-Cruz; Circe Mesa; Tania Carmenate; Darel Martínez; Anet Valdés-Zayas; Enrique Montero; Rolando Pérez
Journal:  J Breast Cancer       Date:  2022-04-26       Impact factor: 2.922

5.  Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models.

Authors:  Juan Garona; Marina Pifano; Maria B Pastrian; Daniel E Gomez; Giselle V Ripoll; Daniel F Alonso
Journal:  Clin Exp Metastasis       Date:  2016-05-05       Impact factor: 5.150

6.  Physicochemical and biological characterization of 1E10 anti-idiotype vaccine.

Authors:  Yoan J Machado; Yamilet Rabasa; Raquel Montesinos; José Cremata; Vladimir Besada; Dasha Fuentes; Adolfo Castillo; Kathya R de la Luz; Ana M Vázquez; Martin Himly
Journal:  BMC Biotechnol       Date:  2011-11-22       Impact factor: 2.563

7.  Malignant myoepithelial cells are associated with the differentiated papillary structure and metastatic ability of a syngeneic murine mammary adenocarcinoma model.

Authors:  Viviana Bumaschny; Alejandro Urtreger; Miriam Diament; Martín Krasnapolski; Gabriel Fiszman; Slobodanka Klein; Elisa Bal de Kier Joffé
Journal:  Breast Cancer Res       Date:  2004-01-15       Impact factor: 6.466

8.  TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling.

Authors:  Paloma Bragado; Yeriel Estrada; Falguni Parikh; Sarah Krause; Carla Capobianco; Hernan G Farina; Denis M Schewe; Julio A Aguirre-Ghiso
Journal:  Nat Cell Biol       Date:  2013-10-27       Impact factor: 28.824

9.  Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines.

Authors:  Georgina A Cardama; Maria J Comin; Leandro Hornos; Nazareno Gonzalez; Lucas Defelipe; Adrian G Turjanski; Daniel F Alonso; Daniel E Gomez; Pablo Lorenzano Menna
Journal:  Anticancer Agents Med Chem       Date:  2014       Impact factor: 2.505

10.  Quantitation of TGF-β proteins in mouse tissues shows reciprocal changes in TGF-β1 and TGF-β3 in normal vs neoplastic mammary epithelium.

Authors:  Kathleen C Flanders; Yu-An Yang; Michelle Herrmann; JinQiu Chen; Nerissa Mendoza; Amer M Mirza; Lalage M Wakefield
Journal:  Oncotarget       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.